US equities |
NVDA $236.86 ▲+1.24% SPCX $165.14 ▲+3.89% MU $1,064.35 ▼-0.98% TSLA $378.99 ▲+2.27% MSFT $526.50 ▲+1.73% INTC $116.97 ▼-1.98% SNDK $1,723.03 ▲+0.18% AMD $628.25 ▼-0.89%
FinancialContent

Articles published by SciSparc Ltd

< Previous 1 2 3 4 5 Next >
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces 1-for-21 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces Publication of Japanese Patent Application
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
News headline image
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC TSX-V:MIZA-P
News headline image
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
< Previous 1 2 3 4 5 Next >